Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470472 | 0.98 | KDR (0.51) | KDRTBK1CHEK1CDK7 | |
| SCHEMBL6125747 | 0.98 | KDR (0.51) | KDRTBK1CHEK1CDK7 | |
| SCHEMBL6126202 | 0.89 | TBK1 (0.41) | KDRTBK1 | |
| SCHEMBL29470305 | 0.89 | TBK1 (0.41) | KDRTBK1 | |
| SCHEMBL29470467 | 0.89 | KDR (0.56) | KDRTBK1 | |
| SCHEMBL6125778 | 0.89 | KDR (0.56) | KDRTBK1 | |
| SCHEMBL20055752 | 0.88 | CHEK1 (0.46) | KDRTBK1CHEK1 | |
| SCHEMBL29470371 | 0.87 | SIK2 (0.38) | KDRTBK1CHEK1CDK7KCNH2 | |
| SCHEMBL6125773 | 0.87 | SIK2 (0.38) | KDRTBK1CHEK1CDK7KCNH2 | |
| SCHEMBL6125718 | 0.86 | KDR (0.49) | KDRTBK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885TBK1 2106/4885CHEK1 395/4885 |
| US-11186593-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | KDR 4125/4885TBK1 2106/4885CHEK1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.